• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Finer Mitchell H.

    3/31/25 4:01:09 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PEPG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Finer Mitchell H.

    (Last) (First) (Middle)
    C/O PEPGEN INC.
    321 HARRISON AVE., 8TH FLOOR

    (Street)
    BOSTON MA 02118

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PepGen Inc. [ PEPG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/27/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.61 03/27/2025 A 26,000 03/27/2026(1) 03/26/2035 Common Stock 26,000 $0 26,000 D
    Explanation of Responses:
    1. The option shall vest as follows: 1/3 on the first anniversary of such Outside Director's election to the Board of Directors, and the remainder ratably in equal monthly installments over the remaining two years, provided, however, that all vesting shall cease if the individual ceases to serve as a director of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting.
    /s/ Mary Beth DeLena 03/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PEPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEPG

    DatePrice TargetRatingAnalyst
    12/16/2024$3.00Neutral → Underperform
    BofA Securities
    7/31/2024$12.00Buy → Neutral
    BofA Securities
    12/21/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $PEPG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technical Officer Kasraian Kasra was granted 16,750 shares (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      5/21/25 4:47:34 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kasraian Kasra

      3 - PepGen Inc. (0001835597) (Issuer)

      5/21/25 4:00:51 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Mcarthur James G bought $13,550 worth of shares (10,000 units at $1.35), increasing direct ownership by 10% to 113,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/22/25 7:01:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Leadership Updates

    Live Leadership Updates

    See more
    • PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

      5/20/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Announces Appointment of Two New Directors to its Board

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies

      3/31/25 4:05:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l

      8/20/24 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

      5/20/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      – Reported positive DM1 patient data with mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – FREEDOM-DM1 data from 15 mg/kg cohort expected in the second half of 2025 – – CONNECT1-EDO51 data from 10 mg/kg cohort expected in the third quarter of 2025 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025. "Our EDO platform's unique ability to efficiently deliver oligonucleotides into the

      5/8/25 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 1:30pm ET. A webcast of the corporate presentation will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentation date. About

      4/2/25 4:05:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Mcarthur James G bought $13,550 worth of shares (10,000 units at $1.35), increasing direct ownership by 10% to 113,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/22/25 7:01:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Mcarthur James G bought $47,725 worth of shares (41,500 units at $1.15), increasing direct ownership by 66% to 103,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/9/25 7:40:15 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oxford Science Enterprises Plc bought $10,559,640 worth of shares (879,970 units at $12.00), increasing direct ownership by 23% to 4,755,388 units (SEC Form 4) (Amendment)

      4/A - PepGen Inc. (0001835597) (Issuer)

      4/9/24 5:24:38 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PepGen Inc.

      SC 13G/A - PepGen Inc. (0001835597) (Subject)

      11/14/24 4:31:29 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by PepGen Inc.

      SC 13G - PepGen Inc. (0001835597) (Subject)

      11/14/24 11:10:10 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PepGen Inc.

      SC 13G/A - PepGen Inc. (0001835597) (Subject)

      11/12/24 8:57:04 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Financials

    Live finance-specific insights

    See more
    • PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

      – Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio

      2/24/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

      – PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation

      7/30/24 4:02:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

      BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived

      3/16/23 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PepGen downgraded by BofA Securities with a new price target

      BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00

      12/16/24 12:07:01 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen downgraded by BofA Securities with a new price target

      BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00

      7/31/24 11:28:59 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on PepGen with a new price target

      H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00

      12/21/22 9:28:36 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

      SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)

      5/15/25 4:32:37 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

      SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)

      5/15/25 8:22:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PepGen Inc. (0001835597) (Filer)

      5/8/25 8:05:08 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care